Tom Witt

Tom Witt has a comprehensive work experience in the pharmaceutical and biotechnology industry. Tom has held various leadership roles in companies like Atara Biotherapeutics, Halozyme Therapeutics, Avanir Pharmaceuticals, Shire, and Amgen.

At Atara Biotherapeutics, they are currently serving as the Sr. Director of Corporate Strategy & Business Development.

At Halozyme Therapeutics, they worked as the Executive Director of Business Development & Strategy, where they successfully led sell-side efforts on a transaction resulting in a $30M upfront payment and identified over 50 potential partner opportunities.

At Avanir Pharmaceuticals, they served as the Sr. Director of Corporate Development, leading two consummated transactions and overseeing business development projects.

At Shire, they held the position of Head of Sales & Marketing Finance, where they were responsible for financial planning and analysis, collaborating with cross-functional leads, and supporting investment decisions.

At Amgen, they held multiple finance roles, including Finance Lead for Biosimilars, Finance Senior Manager for R&D, and Finance Manager for Sales & Marketing. Tom played a significant role in partnership valuation, financial modeling, and strategic support for various teams.

Overall, Tom Witt has a strong background in corporate strategy, business development, financial planning, and analysis in the pharmaceutical and biotechnology industry.

Tom Witt has a Bachelor of Arts degree in Business Economics from UCLA and an MBA in Finance and Strategy from the University of Michigan - Stephen M. Ross School of Business. Tom also obtained a certification in The Harvard Negotiation Intensive from Harvard Law School Executive Education in 2019.